Aldatu Biosciences utilizes its proprietary PANDAA™ technology to develop adaptive PCR diagnostics that can detect new viral variants without the need for assay redesign. This platform addresses the challenge of genomic variability in infectious diseases, enabling reliable and cost-effective testing for pathogens like SARS-CoV-2 and drug-resistant HIV variants.
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Emerging infectious diseases and their evolving variants pose a significant challenge to traditional PCR-based diagnostics, often requiring frequent assay redesign and updates to maintain accuracy. This can lead to delays in testing, increased costs, and potential for inaccurate results, hindering effective disease management and control.
Solution
Aldatu Biosciences offers adaptive PCR diagnostics leveraging their proprietary PANDAA™ technology, which enables detection of new viral variants without the need for assay redesign. The PANDAA™ technology uniquely corrects for sequence diversity through a process called adaptation, proactively accounting for genomic variation that may arise in future viral variants. This approach ensures the enduring integrity of molecular diagnostics, providing fast, reliable, and cost-effective tests for infectious diseases. The platform supports high-throughput testing, improving patient healthcare access and outcomes in the face of evolving pathogens.
Target Audience
The primary target audience includes healthcare providers, hospitals, employers, schools, NGOs, and governments requiring reliable and adaptable diagnostic tools for infectious diseases.
Features
- PANDAA™ technology enables target detection in highly variable genomic regions using RT-PCR.
- Adaptive PCR approach ensures detection of new viral variants without assay redesign.
- Proactive correction for sequence diversity accounts for future genomic variations.
- Development of diagnostic tests for SARS-CoV-2, Lassa virus, Crimean-Congo Hemorrhagic Fever Virus, Ebola, Marburg, and drug-resistant HIV variants.
- High-throughput and low-cost platform improves patient healthcare access.
- Offers both diagnostic testing services through a CLIA-certified lab and diagnostic kits.